Objectives: To describe changes in the prevalence of comorbidities and risk factors among HIV-positive individuals in the EuroSIDA study. Methods: Baseline demographics and prevalence of comorbidities were described. Factors associated with the prevalence of chronic kidney disease (CKD) and cardiovascular disease (CVD) were assessed by logistic regression modelling using generalized estimating equations. Individuals in the 2014 cohort had higher odds for CKD (unadjusted OR 2.62, 95% CI 2.30-2.99, P < 0.0001) and CVD (OR 1.88, CI 1.68-2.10, P < 0.0001), but after multivariable adjustment for age group, comorbidities and other factors, year of cohort was no longer significantly associated with the odds of CKD [adjusted OR (aOR) Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
Introduction
The availability of potent combination antiretroviral therapy (cART) and improved treatment and linkage to care now allow people living with HIV (PLWHIV) to achieve life expectancies close to or the same as those for the general population [1] [2] [3] and led to concomitant aging of the HIV-positive population. In high-income countries in Europe and North America, it is estimated that approximately a third of HIV-positive adults are now aged at least 50 years [4, 5] . Increases in life expectancy have been accompanied by increases in the prevalence of non-AIDS-related comorbidities such as cardiovascular disease (CVD), chronic kidney disease (CKD) or diabetes in PLWHIV [6 -8] . Several cohort studies have described increases in comorbidities, particularly in CVD, CKD, osteoporosis and frailty in the older PLWHIV population [9] [10] [11] [12] compared with the general population. This has been attributed to aging and life-style related factors, but also as consequences of HIV infection and the associated immune exhaustion, inflammation [7, 13, 14] and/or effects of the antiretroviral drugs themselves [15, 16] . Certain antiretroviral drugs may affect the risk of CVD or myocardial infarction [17, 18] , whereas tenofovir disoproxil fumarate (TDF) and some boosted protease inhibitors have been shown to adversely affect kidney function and increase the risk of CKD [19] [20] [21] . A better understanding of the evolution of comorbidities may help to improve the clinical management of PLWHIV, including screening for risk factors and optimal selection of ART to balance HIV outcomes and reduce renal and cardiovascular risks [22] .
To characterize the evolution of the prevalence of comorbidities and related risk factors in the aging PLWHIV population in Europe, we analysed data from individuals under follow-up in the EuroSIDA cohort during 2006 and 2014. We evaluated demographic and clinical characteristics to determine the prevalence of risk factors and comorbidities as the population aged and used modelling to investigate associations with the prevalence of two common comorbidities, which share many risk factors, CKD and CVD.
Methods Study population and data collection
EuroSIDA is a multinational prospective cohort, which has systematically collected epidemiological, clinical, biological and therapeutic data for nearly 23 000 HIVpositive individuals in 35 European countries and in Israel and Argentina since 1994 [23, 24] . Data collection at 6-month intervals is performed by the treating clinicians and constitutes details and dates of all antiretroviral prescriptions, CD4
þ cell count and viral load measurements, laboratory data and clinical events, including both AIDS and non-AIDS events.
For this analysis, two cross-sectional analyses were conducted with individuals under active follow-up during 2006, when creatinine measurements became widely available, and 2014, representing a period with state-ofthe art ART. Individuals were included if they were recruited before 1 January 2007 or 1 January 2015 for the 2006 and 2014 analyses, whereas participants who were lost to follow-up before 01 January 2006 or 01 January 2014, respectively, or those with a current age less than 16 (calculated at the mid-year, i.e. 1 July 2006 or 2014) were excluded. Variables considered were sex, ethnic group, mode of infection and region of Europe, categorized as South (Greece, Italy, Portugal, Spain, Israel and Argentina), West/Central (Austria, Belgium, France, Germany, Luxembourg and Switzerland), North (Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and the United Kingdom) and East (Belarus, Bosnia-Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Georgia, Hungary, Latvia, Lithuania, Poland, Romania, the Russian Federation, Serbia, Slovakia, Slovenia and the Ukraine). BMI (weight divided by the square of height) was categorized as underweight (<18.5), normal (18.5-24.9) , overweight (25-29.9) or obese (>30 kg/m 2 ). Recent HIV diagnosis or recent start of cART (taking at !3 antiretroviral drugs from any class) were defined as occurring during the 2 years prior to the mid-year of interest. Individuals who had a positive hepatitis C virus (HCV) antibody test, RNA test, genotype assay or received HCV treatment prior to mid-2006 or 2014 were considered co-infected with HCV. Hypertension was defined as SBP at least 140 mmHg and/or DBP at least 90 mmHg and/or taking hypertensive medications. Dyslipidaemia was defined as total cholesterol at least 6.2 mmol/l, high-density lipoprotein (HDL) 0.9 mmol/l or less or triglycerides at least 2.3 mmol/l. Estimated glomerular filtration rates (eGFR) were calculated from serum creatinine levels using the CKD-Epidemiology Collaboration creatinine equation [25] , and CKD was a confirmed (two measurements >3 months apart) eGFR of less than 60 ml/min per 1 
Prevalence of risk factors and comorbidities
The prevalence of risk factors and comorbidities for the 2006 and 2014 cohorts is summarized in Table 1 and The D:A:D 5-year CVD risk scores were calculated only for individuals who had eGFR measurements available to allow comparison between those assessed for CKD and CVD risk (Fig. 2b) . Overall the distribution of those with low, medium, high or very-high CVD risks in the five age groups was similar in 2006 and 2014 (Fig. 2b) . As the number of individuals in the oldest age groups (50-60 and !60 years) increased between 2006 and 2014, there was an overall increase in the proportion of individuals with a very high CVD risk (>10%, from 16% in 2006 to 24% in 2014). The Framingham 10-year CVD risk factors [28] showed a similar distribution to the D:A:D CVD risk factors (not shown).
Factors associated
þ counts, HCV infection, smoking status, comorbidies and use of antiretrovirals, the year of the cohort was no longer associated with CKD (aOR 1.07, CI 0.92-1.25, P ¼ 0.37; Fig. 3 ). Older individuals had significantly increased odds of CKD, and after adjustment, women were twice as likely to have CKD compared with men. Those with lower CD4 þ cell counts had higher odds of CKD (Fig. 3) , whereas high viral load (>500 copies RNA/ml) was associated with lower odds of CKD. Individuals with low BMI had a small but nonsignificant increase in the odds for CKD, whereas those who were overweight or obese had somewhat lower odds for CKD, compared with those with normal BMI. Individuals with other risk factors or comorbidities (dyslipidaemia, hypertension, diabetes or CVD) had up to two-fold higher odds for CKD (Fig. 3) . Figure 4 shows the factors associated with having CVD for individuals who had eGFR measurements available (to allow comparison with the analysis of CKD). In univariable analysis, individuals in the 2014 cohort had higher odds of CVD compared with those in 2006 (unadjusted OR 1.88, CI 1.68-2.10, P < 0.0001), but after adjusting for age group, the odds of CKD were similar in 2006 and 2014 (aOR 1.06, CI 0.96-1.18, P ¼ 0.24). After multivariable adjustment for age group, sex, region of Europe, mode of infection, viral load, CD4 þ counts, prior use of abacavir, LPV/r and indinavir, HCV coinfection, BMI, smoking status, hypertension, dyslipidaemia, diabetes, family history of CVD and CKD, the year of the cohort was also not associated with CVD (aOR 0.94, CI 0.83-1.06; P ¼ 0.29; Fig. 4 ). Older individuals had higher odds for CVD (aOR 5.05, CI 3.53-7.23 for those aged 50-60 years and aOR 9.34, CI 6.4-13.65 for those !60) and women were less likely to have CVD. Current and past smokers had higher odds compared with those who had never smoked and the odds for CVD were also increased among those with hypertension (aOR 2.72, CI 2.23-3.31), diabetes (aOR 1.85, CI 1.52-2.24) or CKD (aOR 1.63, CI 1.35-1.97; Fig. 4 ). There was no evidence that the relationship between cohort year and CVD or CKD differed across age groups (test for interaction P ¼ 0.33 for CKD and P ¼ 0.34 for CVD). Several cohort studies have investigated the prevalence of risk factors and comorbidities in PLWHIV compared with the general population and many have identified similar increases of comorbidities in the HIV-positive population, driven by increases in hypertension, dyslipidaemia and obesity. In this study, the prevalence of hypertension increased between 2006 and 2014, and was somewhat higher than previously reported [29, 30] , possibly because of the older age of those included here. More recent studies report a higher burden of hypertension compared with uninfected populations [10, [31] [32] [33] . We also observed high prevalence of dyslipidaemia, based on total and HDL cholesterol and triglyceride levels, in 2006 and 2014. This is comparable with several studies in the USA, which reported dyslipidaemia in 58-80% of participants [32] [33] [34] . Some of this variation may be explained by different definitions, for example, whether triglyceride levels are included or whether lipid levels are based on fasting blood samples. The low prevalence of obesity was similar to data reported for the AgehIV [31] and the Swiss cohort [10] , although considerably lower than seen in cohorts of PLWHIV in the USA [32] [33] [34] [35] , probably because of life-style factors and different demographics as the European cohorts are dominated by MSM.
We observed a small increase in the prevalence of diabetes between 2006 and 2014, similar to that reported in the Swiss HIV cohort [10] . Diabetes appears strongly correlated with age [9] , with lower prevalence reported for younger cohorts [30, 36] , whereas higher prevalence of diabetes (12-18%) was reported in studies in the USA [32] [33] [34] [35] . The prevalence of CKD also increased from 4% in 2006 to 6.9% in 2014, and the odds of CKD increased with time, though this was explained by aging and other risk factors. The increase in CKD is broadly similar to that observed in other European cohorts (e.g. 4.7% in the AgehIV cohort [31, 37] ); by comparison, a lower prevalence of CKD was observed in earlier studies with younger cohorts (2% in the Danish study [11] ), whereas Guaraldi et al. [9] reported 9% CKD in HIV-positive patients aged >50 years.
There has been a focus on CVD in PLWHIV, as HIV infection per se as well as certain antiretrovirals may contribute to CVD risk [17, 18, 20] , and there is a strong association of CVD risk with age. Here we observed an increase in the prevalence of CVD (including myocardial infarction, stroke or invasive cardiovascular procedures) from 3.7% in 2006 to 5% in 2014. This is comparable to the prevalence of cardiovascular conditions reported in other studies. The Danish HIV cohort study reported a prevalence of 3% for myocardial infarction and 4% for stroke [11] , whereas CVD prevalence of 6% has been reported in individuals greater than 50 years old in Italy [9] , and 10% in the AgehIV cohort [31, 37] . Although the unadjusted odds of CVD were strongly associated with year of cohort, after multivariable adjustment, the year was no longer significantly associated with CVD. Increasing age was strongly associated with higher odds of CVD, which is of concern with an aging population of PLWHIV. For younger individuals, the decreased odds of CVD are potentially related to reduced exposure to antiretrovirals that are known to increase CVD risk [17] .
The increase in the prevalence of multiple risk factors and non-AIDS-related comorbidities between 2006 and 2014 is in keeping with what has been observed in many other cohorts [9] [10] [11] [12] , and also reflects the increase in individuals presenting with multiple conditions. Many of the conditions are interrelated; for example, hypertension has been shown to contribute to the risk of developing diabetes, CKD or CVD, diabetes is a risk factor for CKD, and both diabetes and CKD increase the risk of CVD [38, 39] . This highlights the need to address these risk factors and comorbidities together through appropriate medical and lifestyle interventions. Further, as persons are aging and living longer, careful consideration should be given to clinical management of the older PLWHIV population who face additional risks associated with HIV infection, immunosuppression and immune inflammation as well as effects of the antiretrovirals [40] and the need to avoid drug-interactions and polypharmacy [7, 41, 42] .
There are a number of limitations to this study. EuroSIDA is an observational cohort following individuals engaged in care, and the prevalence of comorbidities may be different to other studies of PLWHIV. Given that patient care and treatments are decided by clinicians, there is a possibility of confounding by indication where individuals with poorer prognosis or higher risk factors for certain comorbidities are selected for suitable interventions or specific antiretrovirals. Analyses were restricted to well defined risk factors and comorbidities as information on other age-related comorbidities such as osteoporosis and frailty, lung conditions or neurocognitive status was not available, whereas lack of data on proteinuria, diet and physical activity may represent residual confounding. Identification of CKD was only possible for individuals where serum creatinine measurements were available and our analysis of factors associated with CKD and CVD was restricted to those individuals. The proportion of individuals with eGFR available varied between 2006 and 2014 (89% of individuals in the 2014 cohort had eGFRs, but in 2006, there were only 78% with eGFR and measurements were not available for 66% of those aged <30 years), which might introduce bias. However, similar odds for CVD were seen in a sensitivity analysis when all individuals were included. These is also likely to be some variation in clinical practice and treatment between the centres and regions in EuroSIDA. Among the strengths of the study is the size of the cohort, covering most countries in the European region. Data collection is consistent across all regions with standardized follow-up, quality assurance and low rates of loss to follow-up [43] . Comparable groups of individuals were followed in 2006 and 2014 (73% of those in the 2006 cohort were still under follow-up in 2014), providing an overview of the population of PLWHIV in Europe.
In conclusion, our analysis of risk factors and comorbidities in a large cohort of HIV-positive individuals in Europe has shown an increase in the prevalence of non-AIDS comorbidities, including diabetes, CKD and CVD, along with increased prevalence of hypertension and a high prevalence dyslipidaemia, which was largely explained by the aging of persons included. Higher prevalence of comorbidities was particularly evident for individuals at least 50 years old, highlighting the increase in non-AIDS-related conditions in the aging PLWHIV population. This shows a need for careful management not only to control HIV through optimal selection of ART, but also to address the effect of aging, including screening and regular monitoring of the major comorbidities and risk modification measures and should lead to continued improvement of health outcomes and quality of life in PLWHIV. This analysis was funded by Gilead Sciences who did not influence the analyses presented or the decision to publish study findings.
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